Platform Partnerships Leverage Empirico's Precision Insights Platform and siRCH to offer rapid target discovery and siRNA development services, helping partners de-risk early programs and accelerate path to clinic.

Multi-Modality Potential Empirico's collaboration with AbCellera demonstrates openness to multi-modality programs; there is an opportunity to pursue joint development of antibody-based therapies alongside siRNA or antisense programs with shared ownership structures.

Funding & Alliances Strong investor activity and large antisense deal history indicate Empirico's ability to attract capital and structure licensing or milestone-driven partnerships, making it an attractive candidate for upfronts, milestones, and co-development accords.

Geographic Footprint Two major R&D sites in San Diego and Madison, WI offer geographic diversity for talent, regulatory and clinical operations, and potential regional partnerships or co-located trial initiatives.

Targeted Disease Focus With a focus on genetically validated targets for common diseases with unmet medical need, Empirico provides a compelling value proposition for pharma partners seeking precise patient stratification, biomarkers, and accelerated clinical strategies.